HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Karyopharm Therapeutics (NASDAQ:KPTI) and maintained a $10 price target.
July 18, 2023 | 10:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Karyopharm Therapeutics has received a reiterated 'Buy' rating and a maintained $10 price target from HC Wainwright & Co.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Karyopharm Therapeutics. This could potentially attract more investors, driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100